New drugs launch despite pandemic and FDA surprises
View the Q3 2020 Drug Pipeline Insights Report
At OptumRx, we are committed to providing our clients, members and the broader healthcare community with up-to-date information and support regarding drug access, cost management and notable FDA approvals.
As expected, we’ve seen some delays in drug development due to COVID-19. Still, new drugs will continue to launch. In this report, we discuss the drugs expected to be approved by the FDA in the months ahead as well as the larger trends to watch this year.
Don't want to read the full report? Download the brief summary.